(tisotumab vedotin-tftv)

Prescribing Information
Download Prescribing Information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK.

TIVDAK® (tisotumab vedotin-tftv) for injection, for intravenous use
Initial U.S. Approval: 2021

WARNING: OCULAR TOXICITY

See full prescribing information for complete boxed warning.

•
TIVDAK can cause severe ocular toxicities resulting in changes in vision, including severe vision loss and corneal ulceration. (5.1)
•
Conduct an ophthalmic exam, including an assessment of ocular symptoms, visual acuity, and slit lamp exam of the anterior segment of the eye prior to initiation of TIVDAK, prior to every cycle for the first nine cycles, and as clinically indicated. (2.2, 5.1)
•
Adhere to the required premedication and eye care before, during, and after infusion. (2.2)
•
Withhold TIVDAK until improvement and resume, reduce the dose, or permanently discontinue, based on severity. (2.3, 5.1)

INDICATIONS AND USAGE

TIVDAK is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. (1)

DOSAGE AND ADMINISTRATION

•
For intravenous infusion only. Do not administer TIVDAK as an intravenous push or bolus. Do not mix with, or administer as an infusion with, other medicinal products. (2.4)
•
The recommended dose of TIVDAK is 2 mg/kg (up to a maximum of 200 mg) given as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. (2.1)

DOSAGE FORMS AND STRENGTHS

For Injection: 40 mg as a lyophilized cake or powder in a single-dose vial for reconstitution. (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

•
Peripheral neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold, reduce the dose, or permanently discontinue TIVDAK based on severity. (2.3, 5.2)
•
Hemorrhage: Monitor patients for signs and symptoms of hemorrhage. Withhold, reduce the dose, or permanently discontinue TIVDAK based on severity. (2.3, 5.3)
•
Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur. Withhold TIVDAK for persistent or recurrent Grade 2 pneumonitis and consider dose reduction. Permanently discontinue TIVDAK for Grade 3 or 4 pneumonitis. (2.3, 5.4)
•
Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions, including events of fatal or life-threatening Stevens-Johnson syndrome (SJS), can occur in patients treated with TIVDAK. Immediately withhold TIVDAK for suspected severe cutaneous adverse reactions, including SJS. Permanently discontinue TIVDAK for confirmed Grade 3 or 4 severe cutaneous adverse reactions, including SJS. (2.3, 5.5)
•
Embryo-fetal toxicity: TIVDAK can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. (5.6, 8.1, 8.3)

ADVERSE REACTIONS

The most common (≥25%) adverse reactions, including laboratory abnormalities, were hemoglobin decreased, peripheral neuropathy, conjunctival adverse reactions, nausea, fatigue, aspartate aminotransferase increased, epistaxis, alopecia, alanine aminotransferase increased, and hemorrhage. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Seagen Inc. at 1-855-4SEAGEN or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: Closely monitor for TIVDAK adverse reactions. (7.1)

USE IN SPECIFIC POPULATIONS

•
Moderate or severe hepatic impairment: Exposure to MMAE and adverse reactions are increased. Avoid use. (8.6)
•
Lactation: Advise women not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 11/2025

Medication Guide

MEDICATION GUIDE

MEDICATION GUIDE

This Medication Guide has been approved by the U.S. Food and Drug Administration.     Revised: 11/2025

MEDICATION GUIDE
TIVDAK (TIV-dack)
(tisotumab vedotin-tftv)
for injection, for intravenous use

What is the most important information I should know about TIVDAK?
TIVDAK can cause serious side effects, including:
Eye problems. Eye problems are common with TIVDAK, and can also be severe. TIVDAK can cause changes to the surface of your eye that can lead to dry eyes, eye redness, eye irritation, corneal ulcers, blurred vision, and severe vision loss. Tell your healthcare provider if you develop new or worsening vision changes or eye problems during treatment with TIVDAK.

•
Your healthcare provider will send you to an eye specialist to check your eyes before you start treatment with TIVDAK, before each infusion for your first 9 infusions of TIVDAK, and as needed for any new or worsening signs or symptoms of eye problems.
•
Your healthcare provider will ask if you have any signs or symptoms of eye problems before each infusion. You will be referred to an eye specialist for any new or worsening signs or symptoms of eye problems.
•
Your healthcare provider will prescribe 3 different types of eye drops before you start treatment with TIVDAK. Bring the eye drops with you to each infusion and use them as directed by your healthcare provider to reduce your risk of eye problems:
o
Use 1 drop of steroid eye drops in each eye before each infusion and continue to use your eye drops 3 times a day for 3 days after each infusion.
o
Use vasoconstrictor eye drops right before each infusion.
o
Use lubricating eye drops throughout treatment and for 30 days after your last dose of TIVDAK.
•
Do not wear contact lenses throughout your treatment with TIVDAK unless you are told to use them by your eye specialist.

See “What are the possible side effects of TIVDAK?” for more information about side effects.

What is TIVDAK?
TIVDAK is a prescription medicine used to treat adults with cervical cancer:

•
that has returned or has spread to other parts of the body, and
•
who have received chemotherapy that did not work or is no longer working.

It is not known if TIVDAK is safe and effective in children.

Before receiving TIVDAK, tell your healthcare provider about all of your medical conditions, including if you:

•
have a history of vision or eye problems
•
have numbness or tingling in your hands or feet
•
have bleeding problems
•
have liver problems
•
are pregnant or plan to become pregnant. TIVDAK can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TIVDAK.
Females who are able to become pregnant:
o
Your healthcare provider should do a pregnancy test before you start treatment with TIVDAK.
o
You should use an effective birth control during treatment and for 2 months after your last dose of TIVDAK.
 
Males with female partners who are able to become pregnant:
o
You should use an effective birth control during treatment and for 4 months after your last dose of TIVDAK.
•
are breastfeeding or plan to breastfeed. It is not known if TIVDAK passes into your breast milk. Do not breastfeed during treatment and for 3 weeks after your last dose of TIVDAK.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking TIVDAK with certain other medicines may cause side effects.

How will I receive TIVDAK?

•
TIVDAK will be given to you by intravenous (IV) infusion into your vein over 30 minutes.
•
TIVDAK is usually given every 3 weeks.
•
Your healthcare provider will decide how many infusions you need.
•
Your healthcare provider will put cold packs on your eyes during each infusion.
•
Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with TIVDAK if you have side effects.

What are the possible side effects of TIVDAK?
TIVDAK can cause serious side effects, including: 

•
See “What is the most important information I should know about TIVDAK?”
•
Peripheral neuropathy. Nerve problems called peripheral neuropathy are common with TIVDAK, and can also be serious. Tell your healthcare provider right away if you get numbness or tingling in your hands or feet or muscle weakness.
•
Bleeding (hemorrhage). Bleeding problems are common with TIVDAK, and can also be serious. Tell your healthcare provider or get medical help right away if you get signs or symptoms of bleeding during treatment with TIVDAK, including:
o
blood in your stools or black stools (looks like tar)
o
blood in your urine
o
cough up or vomit blood
o
unusual vaginal bleeding
o
any unusual or heavy bleeding
•
Lung problems. TIVDAK may cause severe or life-threatening inflammation of the lungs that can lead to death. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
•
Severe skin reactions. TIVDAK may cause severe or life-threatening skin reactions that can lead to death. Tell your healthcare provider or get medical help right away if you get signs or symptoms of a severe skin reaction during treatment with TIVDAK, including:
o
skin reactions that look like rings (target lesions)
o
rash or itching that continues to get worse
o
blistering or peeling of the skin
o
painful sores or ulcers in your mouth, nose, throat, or genital area
o
fever or flu-like symptoms
o
swollen lymph nodes

The most common side effects of TIVDAK include:

•
decreased red blood cell counts
•
numbness or tingling in your hands or feet
•
eye problems (conjunctival disorders)
•
nausea
•
tiredness
•
changes in liver function blood tests
•
nosebleed
•
hair loss (alopecia)
•
bleeding (hemorrhage)

TIVDAK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all of the possible side effects of TIVDAK.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of TIVDAK.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you would like more information about TIVDAK, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about TIVDAK that is written for healthcare professionals.

What are the ingredients in TIVDAK?
Active ingredient: tisotumab vedotin-tftv
Inactive ingredients: d-mannitol, l-histidine, l-histidine monohydrochloride, and sucrose.
Manufactured by: Seagen Inc., Bothell, WA 98021
Marketed by: Seagen Inc., Bothell, WA 98021 and Genmab US, Inc., Plainsboro, NJ 08536
U.S. License 2257
TIVDAK® is a trademark owned by Seagen Inc.
©2025 Seagen Inc. and Genmab US, Inc.
LAB-1597-1.0
For more information, go to www.tivdak.com or call 1-855-4SEAGEN

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

 

Submit a medical question for a Pfizer medicine or a vaccine. 

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.